

Suntory Holdings Announces Acquisition of DAIICHI SANKYO HEALTHCARE CO., LTD.

Tokyo, Japan (April 15, 2026) — Suntory Holdings Limited (the “Company”) announced that, at a meeting of its Board of Directors held today, it resolved to acquire all of the shares of DAIICHI SANKYO HEALTHCARE CO., LTD. (“DAIICHI SANKYO HEALTHCARE”) held by DAIICHI SANKYO COMPANY, LIMITED (“DAIICHI SANKYO”), as set forth below.

1. Background to the Acquisition

Guided by its corporate purpose, “To inspire the brilliance of life, by creating rich experiences for people, in harmony with nature,” Suntory Group aims to foster connections among people and deliver joy and inspiration through its products and services. As a comprehensive food and beverage company, the Group offers a diverse portfolio spanning alcoholic beverages, soft drinks, and health foods. In particular, Suntory Wellness Limited has developed foods with function claims and health foods such as *Sesamin EX* and *Locomore*, while Suntory Beverage & Food Limited has pursued the development of products that meet consumers’ growing health-conscious preferences, including Foods for Specified Health Uses (FOSHU) such as *Tokucha* and *Suntory Goma Mugicha*. Through collaboration between these businesses, the Group is also working to create new value for consumers.

DAIICHI SANKYO HEALTHCARE has built a strong portfolio of products with high brand equity, including *LULU*, *LOXONIN*, *MINON*, and *CLEAN DENTAL*. As self-care and self-medication are increasingly promoted in support of extending healthy life expectancy, DAIICHI SANKYO HEALTHCARE has established a strong position as a leading company in Japan’s OTC pharmaceutical market, while also expanding into functional skincare, oral care, and food products. In addition to pharmacies and drugstores, it is strengthening direct-to-consumer sales business and expanding its presence overseas.

By welcoming DAIICHI SANKYO HEALTHCARE into the Suntory Group, the Group expects to expand its business across the self-care and self-medication domains, ranging from prevention to the management and treatment of health conditions. By leveraging the combined strengths of both companies—including brand power, product development expertise, and marketing capabilities—the Group aims to create a unique and comprehensive self-care business that is closely aligned with consumers’ needs and serves as a new driver of growth.

2. Overview of DAIICHI SANKYO HEALTHCARE

(1)	Name	DAIICHI SANKYO HEALTHCARE CO., LTD.		
(2)	Location	3-14-10 Nihonbashi, Chuo-ku, Tokyo		
(3)	Title/Name of representative	Takahiro Uchida, Representative Director, President		
(4)	Business activities	Manufacture and sale of pharmaceuticals, quasi-drugs, cosmetics, medical devices, foods, beverages, etc.		
(5)	Capital	JPY 100 million		
(6)	Date of establishment	December 16, 2005		
(7)	Major shareholders and shareholding ratios	DAIICHI SANKYO COMPANY, LIMITED (100%)		
(8)	Relationship with the Company	Capital relationship	None	
		Personnel relationship	None	
		Business relationship	None	
(9)	Financial results for the last three fiscal years (non-consolidated)			
	Fiscal year end	FY ended March 2023	FY ended March 2024	FY ended March 2025
	Net assets (¥ million)	59,428	65,077	69,321
	Total assets (¥ million)	88,147	98,666	106,006
	Net assets per share (¥)	44,516,014	48,747,517	51,925,848
	Net sales (¥ million)	60,121	65,734	76,049
	Operating income (¥ million)	10,952	12,009	12,922
	Ordinary income (¥ million)	11,083	12,226	13,340
	Net income (¥ million)	7,218	8,159	8,997
	Net income per share (¥)	5,407,160	6,112,150	6,739,661

3. Overview of the acquisition of shares counterparty (DAIICHI SANKYO)

(1)	Name	DAIICHI SANKYO COMPANY, LIMITED	
(2)	Location	3-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo	
(3)	Title/Name of representative	Hiroyuki Okuzawa, Representative Director, President and CEO	
(4)	Business activities	Research and development, manufacture, and sale of pharmaceuticals, etc.	
(5)	Capital	JPY 50 billion	
(6)	Date of establishment	September 28, 2005	
(7)	Total equity	JPY 1,710,549 million (consolidated; as of December 31, 2025)	
(8)	Total assets	JPY 3,821,811 million (consolidated; as of December 31, 2025)	
(9)	Major shareholders and shareholding ratios	The Master Trust Bank of Japan, Ltd. (trust account) (17.38%) Custody Bank of Japan, Ltd. (trust account) (7.15%) Nippon Life Insurance Company (4.60%) STATE STREET BANK AND TRUST COMPANY 505001 (4.53%) JP MORGAN CHASE BANK 385632 (4.11%) STATE STREET BANK WEST CLIENT - TREATY 505234 (1.92%) STATE STREET BANK AND TRUST COMPANY 505223 (1.81%) DEUTSCHE BANK TRUST COMPANY AMERICAS ADR DEPT ACCOUNT (1.46%) JP MORGAN CHASE BANK 385781 (1.45%) GOVERNMENT OF NORWAY (1.41%) (as of September 30, 2025)	
(10)	Relationship with the Company	Capital relationship	None
		Personnel relationship	None
		Business relationship	None
		Status as a related party	None

4. Number of shares to be acquired, acquisition price, and ownership before and after the transaction

(1)	Number of shares held prior to the transaction	0 shares (Voting rights: 0; Voting rights ratio: 0%)
(2)	Number of shares to be acquired	10,000 shares (Voting rights: 10,000)
(3)	Acquisition price	Ordinary shares of DAIICHI SANKYO HEALTHCARE: JPY 246.5 billion
(4)	Number of shares held after the transaction	10,000 shares (Voting rights: 10,000; Voting rights ratio: 100.0%)

Note: The acquisition of shares is scheduled to be conducted in three stages. Upon completion of all three stages, DAIICHI SANKYO HEALTHCARE is expected to become a wholly owned subsidiary of the Company. The acquisition price stated in (3) above represents the total amount for all three stages; the final acquisition price may vary due to the price adjustment provisions set forth in the share transfer agreement.

5. Schedule

(1) Date of Board resolution: April 15, 2026

(2) Date of agreement execution: April 15, 2026

(3) Share transfer execution dates:

First stage: June 1, 2026 - Acquisition of 30% of the voting rights (Total 30% ownership) (planned)

Second stage: June 1, 2027 - Acquisition of 40% of the voting rights (Total 70% ownership) (planned)

Third stage: June 1, 2029 - Acquisition of 30% of the voting rights (Total 100% ownership) (planned)

Note: As described in "4. Number of shares to be acquired, acquisition price, and ownership before and after the transaction," the acquisition of shares will be conducted in three stages. While the first stage is scheduled for June 1, 2026, this schedule may change depending on the progress of procedures under competition laws and other relevant procedures. Following the second stage, DAIICHI SANKYO HEALTHCARE will become a consolidated subsidiary of the Company, and following the third stage, it will become a wholly owned subsidiary of the Company.